The efficacy of drugs targeting diverse mediators of the apoptotic cascade, such as death receptor 5 (DR5), Bcl-2 family proteins, and caspase activity, have been tested in pre-clinical and clinical trials for the treatment of CRC [70]. This evidence concerns the gene TNFRSF10B and colorectal carcinoma.